A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes
published in: Diabetes
date of publication: 2005-06-01
language: English
main subject: type-1 diabetes, antibody, monoclonal antibody
Cites articles 27
- 1993-04-01
Date
Title
Article - wd:Q34421851